Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price target from $24 to $34.
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price target from $24 to $34.